- Home
- CMND
as 07-26-2024 4:00pm EST
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
| Founded: | 2017 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.92 - $16.20 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Clearmind Medicine Inc. News
CMND Breaking Stock News: Dive into CMND Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
GlobeNewswire
10 days ago
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
GlobeNewswire
11 days ago
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
GlobeNewswire
11 days ago
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
GlobeNewswire
15 days ago
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
GlobeNewswire
a month ago
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
GlobeNewswire
a month ago
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
GlobeNewswire
2 months ago
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
Compare CMND vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CMND Clearmind Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.